Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G protein-coupled receptor 162 (GPR162) is a probable G protein-coupled receptor mainly expressed in the human brain. It was identified by genomic analysis within a gene-rich region on chromosome 12p13. The gene encodes an orphan GPCR, meaning its endogenous ligand and specific physiological functions are currently unknown. Several transcript variants exist due to alternative splicing. Although GPR162 is part of the large class A (rhodopsin-like) GPCR family, there is no direct evidence of its involvement in a defined signaling pathway, biological process, or as a therapeutic drug target at present. Associations in genetic studies with disorders such as Fanconi anemia and abdominal obesity-metabolic syndrome 1 have been noted, but there are no mechanistic disease links or clinical targeting strategies validated for this receptor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G protein-coupled receptor 162 (GPR162).